Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Summary

A phase II, single-arm, open-label, multicenter study to assess the efficacy and safety of Surufatinib as a second-line treatment in patients with surgically unresectable or metastatic biliary tract carcinoma

Timeline

Start

2017-01-03

Primary completion

2018-08-17

Completion

2018-11-30

Drugs

Indications